Add 2 More Reports For 20% off

Report Overview

Sexually transmitted diseases are increasing at an alarming rate. In 2023, 31,232 STI cases were reported in the United States. Syphilis cases in women increased from 10% (in 2014) to 30% (in 2023) in women. In addition, congenital syphilis cases increased by 44% in 2023. Therefore, researchers are emphasizing on developing high-quality and potent drugs to manage the disease effectively.

  • Major companies involved in the syphilis pipeline drugs market include Pfizer Inc., Sanofi, Merck & Co., Inc., and GlaxoSmithKline (GSK).
  • Leading drugs currently under pipeline include Cefixime and Linezolid among others.
  • Regulatory authorities such as the United States FDA and EMA play an essential role in syphilis treatment as they are offering breakthrough designations to manage the condition.

Report Coverage

The Syphilis Drug Pipeline Report by Expert Market Research gives comprehensive insights into syphilis drugs currently undergoing syphilis clinical trials. It covers various aspects related to the details of each of these syphilis drugs under development for Syphilis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The syphilis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from syphilis. 

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing syphilis pipeline development activities. Moreover, syphilis collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Syphilis Drug Pipeline Outlook

Syphilis is a bacterial sexually transmitted infection (STI). It can be transmitted via pregnancy and blood transfusion as well. Although curable, it can lead to stillbirths in pregnancy, congenital syphilis in babies and neonatal deaths. Syphilis has three major phases. Primary phase lasts around 21 days and is characterised by the presence of a painless, round sore on the genitals. It may even go unnoticed and heal on its own. Secondary syphilis involves the occurrence of non-itchy rashes on feet, along with greyish lesions on moist areas. Lastly, latent syphilis has no symptoms. However, if left untreated can progress to the final stage after some years. The diagnosis is based on an individual's clinical history, lab tests and physical exams. 

Early stages of syphilis are treated with a benzathine penicillin (BPG) injection. It is also approved for pregnant women with syphilis. Antibiotics such as doxycycline, ceftriaxone or azithromycin can be used as a second-line treatment.

Syphilis Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of syphilis drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase. 

  • Late-Stage Products (Phase 3 and Phase 4) 
  • Mid-Stage Products (Phase 2) 
  • Early-Stage Products (Phase I) 
  • Preclinical and Discovery Stage Products

By Drug Class

EMR’s syphilis therapeutic assessment report covers 50+ drug analyses based on drug classes: 

  • Penicillins
  • Tetracyclines
  • Macrolides
  • Cephalosporins
  • Antibiotics

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration. 

  • Oral 
  • Parenteral 
  • Others 

Syphilis Pipeline Assessment Segmentation, By Phases

The syphilis report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase IV covers a major share of the total clinical trials for syphilis. There are around 13 drugs in phase IV of syphilis drugs.

Syphilis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under syphilis pipeline analysis include penicillins, tetracyclines, macrolides, cephalosporins and antibiotics. The treatment alternative depends on the stage of the disease, patient allergies, and multiple factors. Penicillins (administered through injections) remain the first-in-line treatment for various stages of syphilis. For penicillin-intolerant patients, other antibiotics are advised by healthcare providers.

Syphilis Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR syphilis drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in syphilis clinical trials: 

  • Pfizer Inc.
  • Sanofi
  • GlaxoSmithKline (GSK)
  • Merck & Co., Inc.
  • Bayer AG
  • Abbott Laboratories
  • Hikma Pharmaceuticals
  • Fresenius Kabi

Syphilis Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for syphilis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of syphilis drug candidates.

Cefixime

The University of California, Los Angeles is conducting a study to examine an alternative treatment for syphilis infection. As a part of the study, oral cefixime will be administered to adult patients and they will be asked to visit the clinic 2 weeks after treatment initiation. They will undergo laboratory tests to assess ongoing symptoms.

Linezolid

Currently in Phase 2 of a randomized, open-label, non-comparative, adaptive pilot trial, syphilis dr...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Reasons To Buy This Report

The Syphilis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for syphilis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into syphilis collaborations, regulatory environments, and potential growth opportunities within syphilis pipeline insights.

Key Questions Answered in the Syphilis – Pipeline Insight Report 

  • Which companies/institutions are leading the syphilis drug development?
  • What is the efficacy and safety profile of syphilis pipeline drugs?
  • Which company is leading the syphilis pipeline development activities?
  • What is the current syphilis commercial assessment?
  • What are the opportunities and challenges present in the syphilis drug pipeline landscape?
  • What is the efficacy and safety profile of syphilis pipeline drugs?
  • Which company is conducting major trials for syphilis drugs?
  • Which companies/institutions are involved in syphilis collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in syphilis?

Related Reports

Syphilis Immunoassay Diagnostics Market

Global Clinical Trials Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report Details
Drug Pipeline by Clinical Trial Phase
  • Late-Stage Products (Phase III and Phase IV) 
  • Mid-Stage Products (Phase II) 
  • Early-Stage Products (Phase I) 
  • Preclinical and Discovery Stage Products
Route of Administration
  • Oral 
  • Parenteral 
  • Others
Drug Classes
  • Penicillins
  • Tetracyclines
  • Macrolides
  • Cephalosporins
  • Antibiotics
Leading Sponsors
  • Pfizer Inc.
  • Sanofi
  • GlaxoSmithKline (GSK)
  • Merck & Co., Inc.
  • Bayer AG
  • Abbott Laboratories
  • Hikma Pharmaceuticals
  • Fresenius Kabi
Geographies Covered
  • North America 
  • Europe 
  • Asia Pacific 
  • Others 

Mini Report

10 % Off

USD

1,999

1,799

Single User License

10 % Off

USD

3,099

2,789

Five User License

15 % Off

USD

4,599

3,909

Corporate License

15 % Off

USD

5,999

5,099

Mini Report

One User

USD 1,999

USD 1,799

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 3,099

USD 2,789

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 4,599

USD 3,909

tax inclusive*

  • All Selected Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 5,999

USD 5,099

tax inclusive*

  • All Selected Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124